natgillin/translations-raw huggingface dataset:
The tool according to claim 1, wherein the means for distance control comprises roller balls on a flat ring-shaped surface inside the periphery of the tool. 
Alat prema bilo kojem patentnom zahtjevu od 1 do 4, naznačen time da sredstvo za kontrolu udaljenosti sadrži valjkaste kugle na ravnoj prstenasto oblikovanoj površini unutar oboda alata.
14 hot water outlet 
. izlaz za vruću vodu
Installed at the outlet opening of the extruder was an underwater pelletizing system (Master 1000) of BKG Bruckmann & Kreyenborg Granuliertechnik GmbH in D-48157 Munster/Germany. 
Na odvodu ekstrudera instalira se sustav za peletizaciju pod vodom (Master 1000) BKG Bruckmann & Kreyenborg Granuliertechnik GmbH u D-48157 Mister / Njemačka).
A process for the purification of Perindopril as claimed in claim 5 or 6 wherein in Step(i) the said solvent is acetonitrile. 
Postupak pročišćavanja perindoprila prema zahtjevu 5 ili 6, gdje je u stupnju (1) spomenuto otapalo acetonitril.
a flying shear at an exit end of said rolling mill; 
leteće škare na izlazu valjaonice;
For sanitization, the column was flushed with at least 3 BV of 0.5 M NaOH, the flow stopped for 1 hour, and then the column was rinsed with 6 BV of purified water. 
Za sterilizaciju, kolona je bila oprana s najmanje 3 BV 0.5 M NaOH, protok je zaustavljen nakon I sata, a tada je kolona bila oprana s 6 BV pročišćene vode.
The drug carrier of any one of claims 10 or 11, wherein the lipid molecules comprise one or more lipids selected from the group consisting of HEDC, DODC, HEDODC, DSPE, DOPE, and DC-6-14. 
Pripravak u skladu s patentnim zahtjevom 7, pri čemu lipidne molekule sadrže jedan ili više lipida iz grupe koja se sastoji od i DC-6-14. Pripravak u skladu s patentnim zahtjevom 8, pri čemu lipidne molekule nadalje sadrže
An example for a Hydrophobic charge-induction chromatography resin is MEP-HyperCel® (Boschetti et al., Genetic Engineering Vol. 
Na primjer za kromatografiju s hidrofobnom indukcijom naboja nosač je MEP- HyperCel? (Boschetti i sur., Genetic Engineering Vol.
The process of claim 1, wherein Compound 6 is prepared by a process comprising: 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u:
A distributor comprising at least one coupling system according to claim 1, wherein the first and second base body are respectively implemented as a fluid distributing body. 
Razdjelnik koji sadrži najmanje jedan sustav za spajanje u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je prvo i drugo osnovno tijelo (21) odgovarajuće načinjeno kao tijelo za razdjeljivanje fluida
Example-21 Comparative Bioavailability Data of Nebivolol Tablet of Instant Invention (Test Formulation) v/s Nebilet Tablet (Reference Formulation) 
Podaci o komparativnoj biodostupnosti nebivolol tablete ovog izuma (test pripravak) v/s_nebilet tablete (referentni pripravak)
The reaction mixture was stirred at 75°C for 1 h under Argon. 
Reakcijska smjesa je miješana na 75*C kroz 1 sat pod argonovom atmosferom.
biodegradation of said final product in a composting installation, characterized in that said thermoplastic polymer is a Styrene-Butadiene-Styrene (SBS) block copolymer, or Styrene-Isoprene-Styrene (SIS) block copolymer, or Styrene-Butadiene, Isoprene-Styrene (SBIS) block copolymer. 
biorazgradnja spomenutog završnog proizvoda u postrojenju kompostiranja naznačena time da je spomenuti termoplastični polimer Stiren-Butadien-Stirena (SBS) blok-koplimer, ili Stiren-Isopren-Stiren (SIS) blok-koplimer, ili Stiren-Butadien, Izopren-Stiren (SBIS) blok kopolimer.
These responses demonstrate that the compound of formula Ia, i.e., GDC-0068, in combination with chemotherapeutic agents as specificed in the claims, treat patient's hyperproliferative diseases, and can treat the diseases after prior treatments fail. 
PATENTNI ZAHTJEVI Spoj, naznačen time, da ima formulu Ia: ia, te se u kombinaciji s abirateronom upotrebljava u terapeutskom postupku liječenja hiperproliferativnog poremećaja, pri čemu se kod hiperproliferativnog poremećaja radi o raku prostate.
a T cell receptor B-chain comprising the T cell receptor B-chain sequence of SEQ ID NO: x+1 or a fragment thereof, or a variant of said sequence or fragment;wherein x selected from the group consisting of 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28. An artificial T cell receptor which binds to claudin-6 (CLDN6). 
(i) o-lanac T staničnog receptora koji sadrži sekvencu oa-lanca T staničnog receptora od SEK ID BR: x, i (ii) B-lanac T staničnog receptora koji sadrži sekvencu B-lanca T staničnog receptora od SEK ID BR: x + naznačen time, da je x odabran iz skupine sastavljene od 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26.1 28.
A napkin according to claim 2, wherein said strip of adhesive extends along an edge of said napkin parallel to said first fold. 
Ubrus u skladu s patentnim zahtjevom 2, pri čemu se navedena prianjajuća traka proteže duž ruba navedenog ubrusa paralelno s navedenim prvim naborom.
[Paragraph 1] The compound of Formula I: Wherein 
Spoj, naznačen time, da ima formulu I:
Terms used in the specification have the following meanings: 
Pojmovi upotrijebljeni u opisu imaju slijedeća značenja:
H-indazole-3-carboxamide for the use according to claim 12, wherein said neurodegenerative diseases are selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, and spinal neurodegenerative disorders. 
1H-indazol-3-karboksamid za uporabu prema zahtjevu 12, naznačen time, da su navedene neurodegenerativne bolesti odabrane 1z skupine koju čine Parkinsonova bolest, Alzheimerova bolest, Hungtingtonova bolest i spinalni neurođegenerativni poremećaji.
In some embodiments, the control module is configured to generate a control signal for controlling the switch based on a configuration signal. In a variant, the configuration signal is initiated by an initiation signal, which is transmitted over a power cabling or a radio communication channel. 
Brojilo električne energije u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što inicijacijski signal (37) pokreće konfiguracijski signal (35), gdje se inicijacijski signal šalje energetskim kablovljem (5) ili radio komunikacijskim kanalom.
Administration of the composition: 
Broj objave europskog patenta:
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. 
njegov N-oksid, njegova farmaceutski prihvatljiva sol ili njegov solvat.
The method as claimed in claim 17, wherein said elevations project upward normal to said surface areas of the mouthpiece lining paper in the manner of islands, without any connection to one another. The method as claimed in claim 17, wherein said other substance is applied in the form of a powder, that is to say as a multiplicity of particles which are not connected to one another by a liquid matrix, to said surface areas which are located between said elevations. 
Postupak kao što je navedeno u jednom od zahtjeva 16 do 20, naznačeno time da se od očvrsnutog laka oblikuje struktura od lokalno ograničenih uzvišenja (3, 13, 23) 1 da se na površine (2), koje se nalaze između uzvišenja (3, 13, 23), nanosi supstanca u obliku praha, odnosno kao množina čestica koje međusobno nisu povezane putem tekuće matrice.
RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; 
Ri R'* su neovisno odabrani od H i metila, ili zajedno s atomom ugljika na kojega su vezani, tvore ciklopropilen- skupinu;
Compounds of the formula I as claimed in claims 1 to 17 in which Y is O or S. 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 17, gdje YjeOili S.
The cocrystalline form of the composition according to claim 8 characterized by an X-ray powder diffraction pattern using CuKa radiation having a diffraction peak at diffraction angle 2-theta of 18.2° in combination with one or more of the peaks selected from the group consisting of 16.0°, 25.4°, and 7.0°; with a tolerance for the diffraction angles of 0.2 degrees. 
Sukristalni oblik u skladu s patentnim zahtjevom 11, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu, uz upotrebu CuK., zračenja, s difrakcijskim maksimumom pod difrakcijskim kutom 26 od 7,0", u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 18,8%, 16,1", te 19.3% uz toleranciju za difrakcijske kutove od 0,2%.
The process of any of the previous claims, wherein the remineralized water has a Slit Density Index SDI15 below 5, preferably below 4, and most preferred below 3. The process of any of the previous claims, wherein the remineralized water has a Membrane Fouling Index MFI0.45 below 4, preferably below 2.5, and most preferred below 2. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu remineralizirana voda ima Indeks gustoće proreza SDL;s ispod 5, poželjno ispod 4, te najpoželjnije ispod 3. membrane MFI14,45 ispod 4, poželjno ispod 2.5, najpoželjnije ispod 2.
For purposes of investigations the Zn-HA active agent was dissolved in physiological saline and was used in the concentration range of 0.1 to 5 mg/ml. 
U svrhu ispitivanja Zn-Ha aktivna tvar se otapa u fiziološkoj otopini i koristi se u rasponu koncentracije od 0.1 do 5 mg/ml.
Closing mechanism (1) for refrigerated display cabinets (2), according to any of the preceding claims, characterised in that the frontal displacement means comprise frontally sliding elements. 
Rashladna vitrina s mehanizmom za zatvaranje (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što element za čeono pomicanje pomičnog odjeljka za zatvaranje (3) sadrži čeono kližuće elemente.
When centrifuged, IL-2 compositions of the invention preferably retain at least 97% (e.g. 
Kada su centrifugirani, sastavi IL-2 iz izuma pogodno ostaju barem 97% (na pr.
(in the formula, Lv represents leaving group, Me represents methyl, iPr represents isopropyl, and R represents isopropyl or (2R)-2-fluoropropyl); 
(u formuli Lv predstavlja izlaznu skupinu, Me predstavlja metil, iPr predstavlja izopropil, a R predstavlja izopropil ili (2R)-2-fluorpropil);
A headset apparatus according to any preceding claim including a manual switch apparatus to be worn about the body of a user, the manual switch apparatus including: a switch box means (510) having a body with a manually operable switch device for controlling the operation of a remote communications apparatus; a support means (530) having attachment means for attaching the support means about the body of a user, the support means being shaped to releasably receive at least a part of the body of the switch box means thereby to selectively retain the switch box means in either of two different positions in which the orientation of the switch device relative to the support means is substantially reversed as between said two positions. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da obuhvaćaju ručni sklopni aparat koji se nosi oko tijela korisnika, pri čemu ručni sklopni aparat obuhvaća sljedeće: preklopna kutija (510) koja ima osnovu s ručno operabilnim preklopnim uređajem za upravljanje radom daljinskog komunikacijskog aparata; nosivi element (530) koji ima priključni uređaj za pričvršćivanje nosivog elementa oko tijela korisnika, pri čemu je nosivi element oblikovan za oslobađajući prihvat barem dijela od osnove preklopne kutije, čime se preklopna kutija selektivno zadržava u jednom od dva različita položaja u kojima je orijentacija preklopnog uređaja u odnosu na nosivi element bitno obrnuta nego kao što je između navedena dva položaja.
A dose counter according to claim 2, wherein the gear wheel arranged for engagement by the second ratchet drive pawl is a second gear wheel coupled to the display, the second gear wheel having a circular arrangement of gear teeth. 
Brojač doza u skladu s patentnim zahtjevom 1, pri čemu je kotač sa zupčanikom koji je postavljen za pokretanje drugog pogona zapornog zaklopca (132) drugi kotač sa zupčanikom (130) povezan sa zaslonom, drugi kotač sa zupčanikom (130) ima kružno postavljene zupce zupčanika.
The fusion protein for use of claim 1 or 2, wherein said multi-component enzyme complex is selected from the group consisting of pyruvate dehydrogenase complex (PDHC), [alpha]-ketoglutarate dehydrogenase complex (KGDHC), and branched-chain keto-acid dehydrogenase complex (BCKDHC). 
Fuzijski protem za uporabu iz patentnog zahtjeva 1 ili 2, pri čemu je navedeni višekomponentni enzimski kompleks odabran iz grupe koja se sastoji od kompleksa piruvat dehidrogenaze (PDHC), kompleksa [alfa]-ketoglutarat dehidrogenaze (KGDHC) i kompleksa ketokisele dehidrogenaze razgranatih lanaca (BCKDHC).
The E. coli AcfD (orf3526) protein may have an amino acid sequence selected from the group consisting of SEQ ID NOs:1-19. 
Imunogenski polipeptid prema zahtjevu 1, naznačen time da E. coli AcfD (orf3526) protein ima amino kiselinsku sekvencu izabranu iz skupine koja se sastoji od SEQ ID Br. 1-19.
The invention relates to a pharmaceutical dosage form containing a pharmacologically active agent according to general formula (I) wherein R is —H or —CH3, or a physiologically acceptable salt thereof; 
Farmaceutski oblik doziranja koji sadržava farmakološki aktivno sredstvo prema općoj formuli (D pri čemu je R -H ili -CHo, ili njihova fiziološki prihvatljiva sol, -
at least a tying thread feeder (16) for supplying tying thread (17) to at least one from between said upper crochet (15) and said lower crochet (14); 
- barem uređaj za opskrbu koncem za vezanje (16) za dovođenje konca za vezanje (17) do barem jedne od dvije navedene gornje (15) 1 donje kuke za kukičanje (14);
The unit dosage form according to claim 5, wherein the unit dosage form is a tablet or capsule suitable for oral administration. 
Jedinični dozirni oblik prema zahtjevu 5, gdje je jedinični dozirni oblik tableta ili kapsula prikladna za oralnu primjenu.
the length of L4 is at least twice the length of L2; and 
L; je duljine 1 do $ ostataka amino kiseline; i
a polypeptide portion of a protein that binds to a serum protein, the polypeptide portion being capable of binding to the serum protein. 
polipeptidni dio proteina koji se veže na serumski protein, te se polipeptidni dio može vezati na serumski protein.
The method of claim 1, comprising the subsequent steps of adding a killed whole-cell or acellular pertussis component and a pharmaceutically acceptable excipient. 
Postupak u skladu s patentnim zahtjevima 1-5, naznačen time što uključuje naknadne korake dodavanja jedne ili više cjelostaničnih ili nestaničnih komponenata umrtvljenog uzročnika hripavca i farmaceutski prihvatljivu podlogu.
A pharmaceutical composition for use in the treatment of depression, alcohol addiction and/or dependence, premenstrual tension, premenstrual syndrome or premenstrual dysphoric disorder, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
A liquefied gas treatment system for a vessel, which includes a cargo tank storing liquefied natural gas (LNG), and an engine using the LNG as fuel, the liquefied gas treatment system comprising: 
Sustav za obradu ukapljenog plina za plovilo, koji sadrži spremnik za teret (1;11), u kojem je spremljen ukapljeni zemni plin (LNG), te glavni motor (3) i pomoćni motor (200) koji koristi LNG spremljen u spremniku za teret kao gorivo, gdje sustav za obradu ukapljenog plina sadrži:
The benzyl-containing intermediates (II) can also be prepared by the following process:- 
(b) Intermedijeri koji sadrže benzil (II) mogu se također načiniti slijedećim postupkom: p
A system according to any one of the preceding claims, wherein said at least one first EMR waveguide (130) is coaxially mounted within said reactor chamber (103). 
Sustav prema bilo kojem od prethodnih Zahtjeva, gdje je najmanje jedan prvi valovod (130) za elektromagnetno zračenje (EMR) koaksijalno postavljen unutar navedene komore (103) reaktora.
Hardness of the tablets was 29 N, which was too low. Solid pharmaceutical composition comprising cytisine as an active substance, characterized in that said composition comprise from 20% to 75% by weight of microcrystalline cellulose, glidant and at least one pharmaceutically acceptable excipient chosen from the group comprising: mannitol, colloidal silicon dioxide, calcium hydrogen phosphate, whereby at least 60% of cytisine particles have size from 10 µm to 200 µm. 
Čvrsti farmaceutski sastav koji sadrži citizin kao aktivni sastojak, naznačen time da naveden sastav ne sadrži laktozu i obuhvaća od 20% do 75% masenog udjela mikrokristalične celuloze, sredstvo za podmazivanje i barem jednu farmaceutski prihvatljivu pomoćnu tvar odabranu iz grupe koja obuhvaća: manitol, koloidni silicijev dioksid, kalcijev hidrogen fosfat, pri čemu barem 60% citizinovih čestica ima veličinu od 10 um do 200 um, i farmaceutski sastav je u obliku tablete proizvedene metodom direktne kompresije.
The parasympathetic nervous system plays a major role in regulation bronchomotor tone, and bronchoconstriction is largely the result of reflex increases in parasympathetic activity caused in turn by a diverse set of stimuli. 
Parasimpatički živčani sustav igra glavnu ulogu u regulaciji bronhomotoričkog tonusa, a bronhcokonstrikcija je uglavnom rezultat refleksnih povećanja u parasimpatičkoj aktivnosti prouzrokovanoj pak različitim oblicima stimulacije.
A process for obtaining a mixture of trifluoroacetyl glatiramer acetate, wherein during the process a batch of mixture of polypeptides, each of which consists essentially of alanine, Y-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetate acid, the improvement comprising use of a solution of hydrobromic acid in acetate acid, which solution comprises less than 1000 ppm of metal ion impurities. 
Postupak za dobivanje smjese trifluoracetil glatiramer acetata, naznačen time, da se za vrijeme postupka, šarži smjese polipeptida, od kojih se svaki sastoji od alanina, Y-benzil glutamata, tirozina i trifluoracetil lizina, skida zaštita otopinom bromovodične kiseline u octenoj kiselini, kod čega poboljšanje obuhvaća uporabu otopine bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 1000 ppm nečistoća metalnim ionima i manje od 0,5% slobodnog broma.
Y is a Spacer unit covalently attached to the drug moiety; and y is 0, 1 or 2 
Y je držač razmaka koji je kovalentno priključen na dio molekule lijeka; i y je 0, 1 ili 2;
The present invention therefore provides a compound of formula VII or an acid addition salt or a solvate thereof, wherein R1 is -(CO)NH2, -CH2NH2 or -CN; 
Spoj sa formulom VII ili njegova kisela adicijska sol ili solvat, naznačen time da R, je (CO)NH., -CH>NA, ili -CN;
A process for making a delivery system comprising a chewable product and an active ingredient, said process comprising: providing a heated and liquefied honey, wherein the heated and liquefied honey is obtained by: 
HR P20191538 T1 PATENTNI ZAHTJEVI nn nmnE Proces za pravljenje proizvoda za žvakanje, navedeni proces koji sadrži: a) = osiguravanje zagrijanog i tekućeg meda, pri čemu se zagrijani i tekući med dobiva: i)
The amusement device according to claim 1, wherein several support devices are provided evenly distributed around the circumference of the carrier. The amusement device according to claim 1, wherein the carrier is rotationally symmetrical with respect to the axis of rotation thereof. 
Uređaj za zabavu prema bilo kojem od prethodnih zahtjeva, gdje je izvedeno nekoliko nosećih elemenata (10) raspoređenih ravnomjerno duž opsega nosača (7). . Uređaj za zabavu prema bilo kojem od prethodnih zahtjeva, gdje je nosač (7) izveden kao rotacijski simetričan u odnosu na os (8) rotacije.
The methods of this aspect of the disclosure may further include sequencing the DNA from the bodily fluid of pregnant individual with a nucleic acid sequencer under conditions that produce DNA segment sequences containing the polymorphism sequences. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži sekvenciranje DNK iz tjelesne tekućine trudne osobe upotrebom sekvencera nukleinskih kiselina pod uvjetima koji proizvode sekvence DNK segmenata u kojima je prisutan polimorfizam sekvenci.
Preparation of 2L of sodium citrate approximately 0.2M: 117.64 g of sodium citrate were dissolved in a volumetric flask of 2L and the solution was brought to the final volume with water for injection. 
Priprema 2L natrij citrata približno 0.2M: 117.64 g natrijcitrata otopljeno je u volumetrijskoj boci od 2L i otopina je dovedena do krajnje zapremine sa vodom za injekciju.
In one embodiment of the invention, the heavy chain of the invented antibody comprises a VH domain comprising, consisting essentially of or consisting of the amino acid sequence set forth in SEQ ID NO:14 and/or the light chain of the invented antibody comprises a VL domain comprising, consisting essentially of or consisting of the amino acid sequence set forth in SEQ ID NO:13. 
Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što teški lanac sadrži Vg domenu koja sadrži ili koju čini aminokiselinski slijed iznijet u SEQ ID NO:14 i laki lanac sadrži VL domenu koja sadrži ili koju čini aminokiselinski slijed iznijet u SEQ ID NO: 13.
Preparation of Tablets by Wet Granulation Method 
Priprema tableta postupkom vlažne granulacije
An isothermal process for amplifying a double-stranded nucleic acid target molecule comprising the following steps: 
Izotermni postupak amplifikacije ciljne molekule dvolančane nukleinske kiseline sadrži slijedeće korake:
Pharmaceutical composition according to item 1 characterized in that the composition contains one or more other pharmaceutically acceptable polymers selected from the following group: polysaccharides, PVA, PVP, PEG, alginic acid and its salts and esters. 
Farmaceutski sastav obuhvaća GSNO kao aktivni sastojak zajedno s uobičajenim aditivima i jedan ili više farmaceutski prihvatljivih polimera odabranih iz grupe polisaharida, PVA, PVP, PEG, alginske kiseline i njenih soli, gdje je pH vrijednost sastava približno 8-9.
These horizontal beams are incorporated into the wall element 2 during the laminating process. 
Ove vodoravne grede ugrađene su u zidni element 2 za vrijeme procesa lameliranja.
6 per litre of the formulation, about 2 grams of artificial cherry flavour per litre of the formulation, about 0.10 grams of peppermint oil per litre of the formulation and a sufficient amount of purified water to yield 1 litre of the formulation. 
6 po litri formulacije, oko 2 grama umjetne arome višnje po litru formulacije, oko 0.10 grama ulja peperminta po litri formulacije i neznatnu količinu destilirane vode da bi se dobio prinos od 1 litra formulacije.